Atherosclerosis With Immune Checkpoint Inhibitor Therapy

Sexual Dimorphism in Cardiovascular Biomarkers: Clinical and Research Implications

(2022) Emily S. Lau et al.   CIRCULATION RESEARCH

Sex-Specific Cardiovascular Risks of Cancer and Its Therapies

(2022) Nicholas S. Wilcox et al.   CIRCULATION RESEARCH

Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications

(2022) Jacqueline T. Vuong et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape

(2022) Samik Upadhaya et al.   NATURE REVIEWS DRUG DISCOVERY

Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages’ transition into a pro-inflammatory state

(2022) Laura A. Bosmans et al.   CARDIOVASCULAR RESEARCH

Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors

(2022) Dorien Laenens et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular Disease Risk Among Cancer Survivors

(2022) Roberta Florido et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy

(2021) Ying Jing et al.   JNCI-Journal of the National Cancer Institute

Effect of CD47 Blockade on Vascular Inflammation

(2021) Kai-Uwe Jarr et al.   NEW ENGLAND JOURNAL OF MEDICINE

TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation

(2021) Kui Zang et al.   Frontiers in Oncology

The changing landscape of atherosclerosis

(2021) Peter Libby   NATURE

Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies

(2021) Esther Lutgens et al.   ATHEROSCLEROSIS

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

(2021) Katelyn T. Byrne et al.   CLINICAL CANCER RESEARCH

Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis

(2021) Charles Dolladille et al.   EUROPEAN HEART JOURNAL

Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease

(2021) Michael Lacy et al.   Nature Communications

Immune checkpoint inhibitors for cancer and venous thromboembolic events

(2021) Jingyi Gong et al.   EUROPEAN JOURNAL OF CANCER

Targeting CD47 for cancer immunotherapy

(2021) Zhongxing Jiang et al.   Journal of Hematology & Oncology

An Analysis of Global Research Trends and Top-Cited Research Articles in Cardio-Oncology

(2021) Giselle Alexandra Suero-Abreu et al.   Cardiology Research

Atherosclerosis Immunoimaging by Positron Emission Tomography

(2020) Carlos Pérez-Medina et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis

(2020) Alyssa M. Flores et al.   Nature Nanotechnology

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

(2020) Wenting Zhang et al.   Frontiers in Immunology

Targeted deletion of PD-1 in myeloid cells induces antitumor immunity

(2020) Laura Strauss et al.   Science Immunology

Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors

(2020) Ohad Oren et al.   AMERICAN JOURNAL OF CARDIOLOGY

Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis

(2020) Lili Zhang et al.   CIRCULATION

Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans

(2020) Annelie Shami et al.   EUROPEAN HEART JOURNAL

Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy

(2020) Walter B. Schiffer et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective

(2020) Libin Guo et al.   Frontiers in Immunology

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

(2020) Stephen M. Ansell et al.   Blood Advances

Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in Large Arteries

(2020) Raffaella Calabretta et al.   CIRCULATION

Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque

(2020) Zsofia D. Drobni et al.   CIRCULATION

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

(2020) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics and clinical trial results of agonistic anti‑CD40 antibodies in the treatment of malignancies (Review)

(2020) Da-Ke Li et al.   Oncology Letters

Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice

(2020) Kikkie Poels et al.   Cells

Heterogeneity of T Cells in Atherosclerosis Defined by Single-Cell RNA-Sequencing and Cytometry by Time of Flight

(2020) Holger Winkels et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

(2020) Maria D’Souza et al.   EUROPEAN HEART JOURNAL

The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm

(2020) Quentin Lecocq et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review

(2020) Cinzia Solinas et al.   THROMBOSIS RESEARCH

A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention

(2020) Spencer C Wei et al.   Cancer Discovery

T cell co-stimulator inducible co-stimulatory (ICOS) exerts potential anti-atherosclerotic roles through downregulation of vascular smooth muscle phagocytosis and proliferation

(2020) Zhixiong Zhong et al.   Annals of Translational Medicine

High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients

(2020) Luca Cantini et al.   EUROPEAN JOURNAL OF CANCER

Immunity and Inflammation in Atherosclerosis

(2019) Dennis Wolf et al.   CIRCULATION RESEARCH

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers

(2019) Christopher J. D. Wallis et al.   JAMA Oncology

Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system

(2019) Amir Abbas Momtazi-Borojeni et al.   ATHEROSCLEROSIS

Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment

(2019) Xingzhe Ma et al.   Cell Metabolism

Immunotherapy for cardiovascular disease

(2019) Esther Lutgens et al.   EUROPEAN HEART JOURNAL

Rational design of anti-GITR-based combination immunotherapy

(2019) Roberta Zappasodi et al.   NATURE MEDICINE

Cardiovascular Disease and Cancer: Is There Increasing Overlap?

(2019) Logan Vincent et al.   Current Oncology Reports

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

Increased lymphocyte activation and atherosclerosis in CD47-deficient mice

(2019) Daniel Engelbertsen et al.   Scientific Reports

A Novel Anti-Cd40 Monoclonal Antibody, Iscalimab, for Control of Graves’ Hyperthyroidism – A Proof-Of-Concept Trial

(2019) G J Kahaly et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sex Differences in Circulating Biomarkers of Cardiovascular Disease

(2019) Emily S. Lau et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Individual coronary plaque changes on serial CT angiography: Within-patient heterogeneity, natural history, and statin effects in HIV

(2019) Borek Foldyna et al.   Journal of Cardiovascular Computed Tomography

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

(2019) Kausik K Ray et al.   Lancet Diabetes & Endocrinology

Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis

(2019) Yoshito Zamami et al.   JAMA Oncology

Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis

(2019) Justine L. Newman et al.   CARDIOVASCULAR PATHOLOGY

A population-based study of cardiovascular disease mortality risk in US cancer patients

(2019) Kathleen M Sturgeon et al.   EUROPEAN HEART JOURNAL

Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study

(2019) Jair Bar et al.   EUROPEAN JOURNAL OF CANCER

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

Single-cell immune landscape of human atherosclerotic plaques

(2019) Dawn M. Fernandez et al.   NATURE MEDICINE

Macrophages in Atherosclerosis Regression

(2019) Tessa J. Barrett   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event

(2019) Jennifer Cautela et al.   CANADIAN JOURNAL OF CARDIOLOGY

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

(2019) Federico Nichetti et al.   Cancers

Immune cell census in murine atherosclerosis: cytometry by time of flight illuminates vascular myeloid cell diversity

(2018) Jennifer E Cole et al.   CARDIOVASCULAR RESEARCH

Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection

(2018) Virginia A. Triant et al.   CIRCULATION

Single-Cell RNA-Seq Reveals the Transcriptional Landscape and Heterogeneity of Aortic Macrophages in Murine AtherosclerosisNovelty and Significance

(2018) Clément Cochain et al.   CIRCULATION RESEARCH

Atlas of the Immune Cell Repertoire in Mouse Atherosclerosis Defined by Single-Cell RNA-Sequencing and Mass CytometryNovelty and Significance

(2018) Holger Winkels et al.   CIRCULATION RESEARCH

Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis

(2018) Tom T.P. Seijkens et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

(2018) Sara Valpione et al.   Journal of Translational Medicine

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

(2018) Javid J Moslehi et al.   LANCET

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

(2018) Fabio Conforti et al.   LANCET ONCOLOGY

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

(2018) Michael R. Migden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery

(2018) Yun Xia et al.   CELL

Cardiovascular oncology

(2018) Tom T.P. Seijkens et al.   CURRENT OPINION IN LIPIDOLOGY

Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A U.S. Food and Drug Administration pooled analysis.

(2018) Laleh Amiri-Kordestani et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatotoxicity and Recurrent NSTEMI While on Pembrolizumab for Metastatic Giant Cell Bone Tumor

(2018) Jennifer M. Kwan et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

(2018) Joe-Elie Salem et al.   LANCET ONCOLOGY

Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

(2018) Jun Tang et al.   NATURE REVIEWS DRUG DISCOVERY

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice

(2017) Holger Winkels et al.   EUROPEAN HEART JOURNAL

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD70 limits atherosclerosis and promotes macrophage function

(2017) Dirk Lievens et al.   THROMBOSIS AND HAEMOSTASIS

Overexpression of Cytotoxic T-Lymphocyte–Associated Antigen-4 Prevents Atherosclerosis in MiceHighlights

(2016) Takuya Matsumoto et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy

(2016) Ashley E. Mahne et al.   CANCER RESEARCH

CD80 Is Upregulated in a Mouse Model with Shear Stress-Induced Atherosclerosis and Allows for Evaluating CD80-Targeting PET Tracers

(2016) Romana Meletta et al.   MOLECULAR IMAGING AND BIOLOGY

CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis

(2016) Yoko Kojima et al.   NATURE

Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism

(2016) Wei Yang et al.   NATURE

Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis

(2016) Romana Meletta et al.   EJNMMI Research

Expression of coinhibitory PD-L1 on CD4+CD25+FOXP3+ regulatory T cells is elevated in patients with acute coronary syndrome

(2015) Si-Hui Li et al.   CORONARY ARTERY DISEASE

Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential

(2015) Koen van de Ven et al.   Immunotherapy

PD-1 and Tim-3 Pathways Regulate CD8+ T Cells Function in Atherosclerosis

(2015) Ming-Ke Qiu et al.   PLoS One

Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study

(2014) Venkatesh Mani et al.   INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING

Increased Arterial Inflammation Relates to High-risk Coronary Plaque Morphology in HIV-Infected Patients

(2014) Ahmed Tawakol et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

(2014) Xiaozhou Fan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice

(2014) Clément Cochain et al.   PLoS One

Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men

(2013) Markella V. Zanni et al.   AIDS

T-Cell Immunoglobulin and Mucin Domain 3 Acts as a Negative Regulator of Atherosclerosis

(2013) Amanda C. Foks et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells

(2013) Barbara Dietel et al.   ATHEROSCLEROSIS

T-cell co-stimulation by CD28–CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development

(2013) M.M. Ewing et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE−/− mice

(2012) Kongyang Ma et al.   CARDIOVASCULAR RESEARCH

Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation

(2011) De-xiu Bu et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

(2011) Lukas Baitsch et al.   JOURNAL OF CLINICAL INVESTIGATION

Effect of Two Intensive Statin Regimens on Progression of Coronary Disease

(2011) Stephen J. Nicholls et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis

(2008) Jun Lee et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY